Addex Therapeutics Ltd is a clinical‐stage biotechnology company focused on allosteric modulation of G protein‐coupled receptors (GPCRs) to address a range of neurological and neuropsychiatric disorders. By targeting receptor sites distinct from endogenous ligand binding regions, Addex aims to develop highly selective therapies with improved safety profiles and reduced off-target effects. The company’s research platform integrates structure-based drug design with in-house pharmacological screening, enabling the discovery of novel modulators that fine-tune receptor activity.
The company’s lead pipeline includes dipraglurant, a negative allosteric modulator of the mGlu5 receptor in clinical development for levodopa-induced dyskinesia in Parkinson’s disease, and ADX71149, a positive allosteric modulator of the mGlu2 receptor evaluated for anxiety and other neuropsychiatric indications. In addition to its proprietary programs, Addex actively explores collaborative opportunities to expand its allosteric portfolio, pursuing early-stage discovery projects that leverage its understanding of GPCR biology across inflammation, pain and central nervous system indications.
Founded in 2002 and headquartered in Geneva, Switzerland, Addex maintains research operations in North America and collaborates with academic institutions and pharmaceutical partners worldwide. The company has a history of licensing agreements and strategic alliances that have supported its growth and enabled advancement of its clinical candidates. Addex’s global footprint allows it to engage with regulatory authorities and clinical trial networks across Europe, the United States and Asia.
Led by a seasoned management team and board with extensive experience in pharmaceutical development, Addex combines scientific leadership with industry expertise in drug discovery, clinical research and regulatory affairs. The company’s executives and scientific advisors bring backgrounds from leading biotech and pharmaceutical organizations, guiding Addex through early discovery, translational development and clinical execution toward its goal of delivering new therapies for patients with unmet medical needs.
AI Generated. May Contain Errors.
Free ADDXF Stock Alerts